PEOPLE ON THE MOVE
Immune Pharmaceuticals
Immune Pharmaceuticals has appointed Miri Ben-Ami as president of its Israeli subsidiary, as well as executive vice president of oncology.
The US-headquartered company has made Monica Luchi chief medical officer and head of drug development.
The company recently began Phase II trials for its monoclonal antibody bertilimumab for bullous pemphigoid.
Ben-Ami most recently worked as CEO of Aposense, a public biotech developing oncology therapeutics and molecular imaging diagnostics. She previously worked for nine years at Teva.
Luchi has held senior immunology and inflammation positions at Novartis, Incyte and most recently, Mesoblast.
